Lilly’s Olumiant adds to remdesivir benefit in NIH COVID-19 study

Data from NIAID’s ACTT-2 study mark Lilly’s rheumatoid arthritis drug as the first targeted immunomodulator to succeed in a randomized, controlled Phase III study in hospitalized COVID-19 patients, and support combining immunotherapies with Gilead’s remdesivir to improve outcomes.

Not yet determined is whether the combination of Olumiant baricitinib and Veklury remdesivir reduced death...